Gapping up
In reaction to strong earnings/guidance:
- N/A.
Other news:
- TLGT +19.3% (received FDA approval of the Company's abbreviated new drug application of Diflorasone Diacetate Ointment 0.05%; planning to launch this product in the third quarter of 2018)
- APTO +10.5% (enters into a license agreement with CrystalGenomics for China rights to CG-806 to develop and commercialize CG-806)
- NVAX +4.3% (New England Journal of Medicine publishes Novavax' NanoFlu clinical trial data)
- PVTL +3.8% (continued strength following earnings)
- ARGX +2.6% (announces results from its Phase 1 clinical trial evaluating a subcutaneous formulation of efgartigimod)
- GSK +2.1% (GSK received FDA update concerning pending approval for generic Advair Diskus; FDA identified minor deficiencies to be relayed in Complete Response Letter on June 27, 2018)
- NUAN +2% (following CNBCFastMoney mention)
- SAGE +1.3% (SAGE Therapeutics and Shionogi & Co enter strategic collaboration to develop and commercialize SAGE-217)
Analyst comments:
- NUS +1% (initiated with a Buy at Jefferies)
![]()